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Use of high-cost operative procedures by medicare beneficiaries en-
rolled in for-profit and not-for-profit health plans
Schneider EC, Zaslavsky AM, Epstein AN. N Engl J Med 2004;350:143-50.
Conclusion: Rates of high-cost procedures are equal among beneficia-
ries enrolled in not-for-profit health plans and those enrolled in for-profit
health plans.
Summary: The authors tested the hypothesis that 12 common high-
cost procedures (cardiac catheterization, CABG, percutaneous transluminal
coronary angioplasty, reduction of femur fracture, total hip replacement,
total knee replacement, carotid endarterectomy, partial colectomy, open and
laparoscopic cholecystectomy, prostatectomy, and hysterectomy) would be
lower in for-profit health plans compared with not-for-profit health plans.
Comparisons were made between 3,726,065 Medicare beneficiaries 65 years
of age or older enrolled in 254 health plans.
Rates of cardiac catheterization, percutaneous transluminal coronary
angioplasty, CABG, and carotid endarterectomy were higher in for-profit
health plans than in not-for-profit health plans. Rates of the other proce-
dures analyzed were similar in the two types of health plans. When charac-
teristics of the health plans and enrollee case mix were adjusted for, for-profit
plans had significantly higher rates than not-for-profit plans in 2 of the 12
procedures. With no procedure was there a lower rate in the for-profit health
plans. The findings were independent of geographic location.
Comment: This study should be reassuring to patients enrolled in
for-profit health plans. For-profit health plans have long stressed that they do
not make money by rationing care but rather by delivering more efficient
care. The findings of this report suggest some element of truth to these
claims.
Venous claudication in iliofemoral thrombosis: Long-term effects on
venous hemodynamics, clinical status, and quality of life
Delis KT, Bountouroglou B, Mansfield AO. Ann Surg 2004;239:118-26.
Conclusion: Forty-four percent of patients with iliofemoral deep ve-
nous thrombosis (DVT) demonstrate claudication with treadmill testing. In
15% claudication is sufficiently severe to interrupt walking.
Summary: The authors studied 39 patients with previous iliofemoral
DVT. Patients with arterial insufficiency, previous venous thrombectomy or
venous thrombolysis were excluded. The median age of the 39 study patients
was 46 years, with a median follow-up of 5 years (range, 1-23 years). Patients
were classified according to the CEAP and venous clinical severity score
(VCSS) systems. Initial claudication distance and absolute claudication
distance was assessed with treadmill walking (3.5 km/h, 10%). Patients were
also studied with air plethysmography and venous duplex scanning. Quality
of life was evaluated with the SF 36.
All limbs with iliofemoral DVT demonstrated reflux with vascular
laboratory testing. Compared with healthy subjects, and adjusting for age
and sex, patients with iliofemoral DVT had impaired general health (P 
.001), social function (P  .047), mental health (P  .043), and physical
functioning (P .02). On treadmill testing, 43.6% (95% confidence interval,
27%-60%) developed claudication in the limb with previous iliofemoral DVT
at a mean of 130 meters (range, 105-268 meters). Treadmill walking was
discontinued in 15.4% secondary to claudication at a mean distance of 241
meters (range, 137-298 meters). Limbs with prior iliofemoral DVT also had
greater impairment as assessed by the CEAP and VCSS systems (P .001).
Five limbs with iliofemoral DVT developed venous ulceration compared
with none of the control limbs.
Comment: The incidence of venous ulceration and the prevalence of
venous hemodynamic abnormalities documented in this study after iliofem-
oral DVT are consistent with previous reports. The study, however, suggests
a higher impact of iliofemoral DVT on ambulation than previously reported.
Normal D-dimer levels do not exclude thrombotic complications in
trauma patients
Wahl WL, Ahrans KS, Zajkowski PJ, et al. Surgery 2003;134:529-33.
Conclusion: In the first 4 days following traumatic injury, a negative
D-dimer does not exclude deep venous thrombosis (DVT) or pulmonary
embolism (PE).
Summary: Prevailing consensus is that a negative D-dimer test is highly
specific for excluding venous thromboembolic (VTE) disease. The authors
evaluated the ability of D-dimer testing to exclude VTE in high-risk trauma
patients. Adult trauma patients admitted between March 1999 to March
2001 with an injury severity score (ISS) 9 and an expected length of stay
3 days were eligible for the study. Enrolled patients underwent bilateral
lower extremity duplex ultrasound and D-dimer levels within 36 hours of
admission, at day 3 to 4 following admission, at day 7, and then weekly until
discharge. D-dimer assays were performed using the dimertest latex assay.
During the study period, 97 patients were enrolled—17% of potentially
eligible patients. DVT was diagnosed in 23 patients, with 18 DVTs detected
within the first week. Five DVT patients had normal D-dimer levels. All 5 of
the false negative D-dimer tests occurred in patients who were diagnosed
with DVT or PE within 4 days of admission. The false negative rate for DVT
by D-dimer assay was 24%, sensitivity was 76%, and the overall negative
predictive value was 92%. The negative predictive value of a D-dimer test
after the first 4 days following injury was 100%.
Comment: Sensitivity and specificity for D-dimer is assay-specific. The
method of D-dimer testing employed in this study is relatively cumbersome
compared with other available assays. It is therefore unlikely that the results
of this study will be directly applicable to most centers. Nevertheless, the
study suggests that, without validation of individual assays, D-dimer alone is
problematic for excluding VTE in the recently admitted trauma patient.
Fibrinogen predicts mortality in high risk patients with peripheral
arterial disease
Doweik L, Maca T, Schillinger M, et al. Eur J Vasc Endovasc Surg 2003;
26:381-6.
Conclusion: Elevated fibrinogen levels in patients with peripheral
arterial disease (PAD) predict an increased risk of fatal cardiovascular com-
plications.
Summary: The authors studied the relationship of fibrinogen levels
and mortality in patients with PAD. A total of 486 patients with PAD and
cardiovascular comorbidities were analyzed with respect to atherosclerotic
risk factors and fibrinogen levels. Fibrinogen levels were determined at
presentation, and patients were followed by for a median of 7 years for
all-cause and cardiovascular mortality.
Survival at 1, 3, 5, and 10 years was 96%, 91%, 83%, and 67%,
respectively. Of the 138 patients (28%) who died, 70% died of cardiovascular
complications. Patients with fibrinogen levels in the highest third and fourth
quartiles had a significantly increased risk for all-cause mortality (hazard ratio
[HR], 1.87 and 1.90, respectively; P  .025 and P  .020, respectively)
when compared with patients in the lowest fibrinogen quartile. The presence
of diabetes mellitus and critical limb ischemia were also independent predic-
tors of mortality (HR 2.08; P  .001 and 1.88, P  .001, respectively).
Comment: Fibrinogen is required for fibrin formation. Fibrin forms
the basic plug of coagulation and platelet aggregation in arterial thrombi.
Since the end point of atherosclerosis is thrombosis, patients with athero-
sclerosis and hyperfibrinogenemia may be candidates for treatment with
fibrate medications that combine lipid and fibrinogen-lowering effects.
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